After users began sharing videos online in early 2023 showing clumps of hair falling out, DailyMail.com reported that Ozempic may cause hair loss. Now, a new study has confirmed these anecdotal reports.
The research tracked nearly 3,000 Americans using semaglutide (the active ingredient in Ozempic and Wegovy), comparing it to users of an older weight loss drug, bupropion-naltrexone (Contrave). The results showed that semaglutide users were 52% more likely to experience hair loss than those taking Contrave. For women, the risk of hair loss with semaglutide was even higher, doubling that of those on Contrave.
While the overall risk remains low (around 1% of patients experienced hair loss), the study suggests the rapid weight loss caused by semaglutide (up to 2 pounds a week) could stress the body, disrupting the natural hair growth cycle and causing hair to shed more quickly. Researchers noted that this rapid weight loss could trigger many hairs to fall out simultaneously.
Additionally, other weight loss drugs, such as tirzepatide (Mounjaro), have been linked to similar side effects. The information leaflets for both Ozempic and Wegovy do list hair loss as a potential side effect.
In the study, which analyzed data from the healthcare claims database IQVIA PharMetrics Plus for Academics, 1,926 patients using semaglutide were included. Of these, 23 (or 1.1%) reported hair loss. These patients were, on average, 55 years old, with 53% being female, and 5% taking steroids—another known cause of hair loss.
In comparison, 1,348 Contrave users were included, and 27 (or 2%) reported hair loss. The Contrave group was, on average, younger (46 years old), with 80% being female. After accounting for factors like age, sex, and steroid use, the researchers found that those using semaglutide had a 52% higher chance of experiencing hair loss.
The scientists also suggested that semaglutide could cause hair loss due to a lack of nutrients, either from eating less or due to side effects such as vomiting.
The study, conducted by researchers from the University of British Columbia, highlighted the increased risk of hair loss in women using semaglutide. However, they acknowledged that further studies are needed to confirm the connection between semaglutide and hair loss.
While hair loss is the latest side effect linked to Ozempic, other common side effects include nausea, diarrhea, and stomach pain. Approximately 13% of US adults have tried semaglutide, with its popularity growing due to its rapid weight loss benefits, especially among Hollywood celebrities.
In response to the study, Novo Nordisk, the maker of Ozempic, reaffirmed its confidence in the benefit-risk profile of its GLP-1 medicines, stating that they remain effective when used as indicated.
Related Topics:
Study Links Wegovy to Increased Risk of Hair Loss
Who Can Access Weight Loss Drugs on the NHS in Scotland?
Drivers Cautioned Over Potential Side Effects of Weight-Loss Injections
